{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T19:59:43Z","timestamp":1790539183388,"version":"4.1.0"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T00:00:00Z","timestamp":1659484800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T00:00:00Z","timestamp":1659484800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s00259-022-05887-6","type":"journal-article","created":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T03:23:35Z","timestamp":1659497015000},"page":"3964-3972","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["[64Cu]Cu-ATSM: an emerging theranostic agent for cancer and neuroinflammation"],"prefix":"10.1007","volume":"49","author":[{"given":"Fang","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijun","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,3]]},"reference":[{"key":"5887_CR1","doi-asserted-by":"publisher","unstructured":"Nam B, Lee W, Sarkar S, Kim JH, Bhise A, Park H, et al. In vivo detection of hydrogen sulfide in the brain of live mouse: application in neuroinflammation models. Eur J Nucl Med Mol Imaging. 2022.\u00a0https:\/\/doi.org\/10.1007\/s00259-022-05854-1.","DOI":"10.1007\/s00259-022-05854-1"},{"key":"5887_CR2","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.2967\/jnumed.119.229443","volume":"61","author":"P Jain","year":"2020","unstructured":"Jain P, Chaney AM, Carlson ML, Jackson IM, Rao A, James ML. Neuroinflammation PET imaging: current opinion and future directions. J Nucl Med\u202f: Off Publ Soc Nucl Med. 2020;61:1107\u201312. https:\/\/doi.org\/10.2967\/jnumed.119.229443.","journal-title":"J Nucl Med : Off Publ Soc Nucl Med"},{"key":"5887_CR3","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/s2215-0366(20)30255-8","volume":"7","author":"JH Meyer","year":"2020","unstructured":"Meyer JH, Cervenka S, Kim M-J, Kreisl WC, Henter ID, Innis RB. Neuroinflammation in psychiatric disorders: PET imaging and promising new targets. Lancet Psychiat. 2020;7:1064\u201374. https:\/\/doi.org\/10.1016\/s2215-0366(20)30255-8.","journal-title":"Lancet Psychiat"},{"key":"5887_CR4","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/s1474-4422(20)30346-x","volume":"19","author":"WC Kreisl","year":"2020","unstructured":"Kreisl WC, Kim M-J, Coughlin JM, Henter ID, Owen DR, Innis RB. PET imaging of neuroinflammation in neurological disorders. Lancet Neurol. 2020;19:940\u201350. https:\/\/doi.org\/10.1016\/s1474-4422(20)30346-x.","journal-title":"Lancet Neurol"},{"key":"5887_CR5","doi-asserted-by":"publisher","first-page":"448","DOI":"10.7150\/thno.6592","volume":"3","author":"C Wu","year":"2013","unstructured":"Wu C, Li F, Niu G, Chen X. PET imaging of inflammation biomarkers. Theranostics. 2013;3:448\u201366. https:\/\/doi.org\/10.7150\/thno.6592.","journal-title":"Theranostics"},{"key":"5887_CR6","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.apsb.2020.08.006","volume":"11","author":"L Zhang","year":"2021","unstructured":"Zhang L, Hu K, Shao T, Hou L, Zhang S, Ye W, et al. Recent developments on PET radiotracers for TSPO and their applications in neuroimaging. Acta Pharm Sin B. 2021;11:373\u201393. https:\/\/doi.org\/10.1016\/j.apsb.2020.08.006.","journal-title":"Acta Pharm Sin B"},{"key":"5887_CR7","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.brainresbull.2006.10.029","volume":"72","author":"YF Tai","year":"2007","unstructured":"Tai YF, Pavese N, Gerhard A, Tabrizi SJ, Barker RA, Brooks DJ, et al. Imaging microglial activation in Huntington\u2019s disease. Brain Res Bull. 2007;72:148\u201351. https:\/\/doi.org\/10.1016\/j.brainresbull.2006.10.029.","journal-title":"Brain Res Bull"},{"key":"5887_CR8","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1046\/j.1471-4159.2003.01568.x","volume":"84","author":"BA Weissman","year":"2003","unstructured":"Weissman BA, Raveh L. Peripheral benzodiazepine receptors: on mice and human brain imaging. J Neurochem. 2003;84:432\u20137. https:\/\/doi.org\/10.1046\/j.1471-4159.2003.01568.x.","journal-title":"J Neurochem"},{"key":"5887_CR9","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.parkreldis.2009.05.005","volume":"16","author":"AL Bartels","year":"2010","unstructured":"Bartels AL, Willemsen AT, Doorduin J, de Vries EF, Dierckx RA, Leenders KL. [11C]-PK11195 PET: quantification of neuroinflammation and a monitor of anti-inflammatory treatment in Parkinson\u2019s disease? Parkinsonism Relat Disord. 2010;16:57\u20139. https:\/\/doi.org\/10.1016\/j.parkreldis.2009.05.005.","journal-title":"Parkinsonism Relat Disord"},{"key":"5887_CR10","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.neurobiolaging.2007.11.005","volume":"30","author":"S Venneti","year":"2009","unstructured":"Venneti S, Lopresti BJ, Wang G, Hamilton RL, Mathis CA, Klunk WE, et al. PK11195 labels activated microglia in Alzheimer\u2019s disease and in vivo in a mouse model using PET. Neurobiol Aging. 2009;30:1217\u201326. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2007.11.005.","journal-title":"Neurobiol Aging"},{"key":"5887_CR11","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s00259-021-05309-z","volume":"49","author":"J Schubert","year":"2021","unstructured":"Schubert J, Tonietto M, Turkheimer F, Zanotti-Fregonara P, Veronese M. Supervised clustering for TSPO PET imaging. Eur J Nucl Med Mol Imaging. 2021;49:257\u201368. https:\/\/doi.org\/10.1007\/s00259-021-05309-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5887_CR12","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1007\/s00259-018-3974-7","volume":"45","author":"M Unterrainer","year":"2018","unstructured":"Unterrainer M, Mahler C, Vomacka L, Lindner S, Havla J, Brendel M, et al. TSPO PET with [(18)F]GE-180 sensitively detects focal neuroinflammation in patients with relapsing-remitting multiple sclerosis. Eur J Nucl Med Mol Imaging. 2018;45:1423\u201331. https:\/\/doi.org\/10.1007\/s00259-018-3974-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5887_CR13","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13550-017-0340-x","volume":"7","author":"L Vomacka","year":"2017","unstructured":"Vomacka L, Albert NL, Lindner S, Unterrainer M, Mahler C, Brendel M, et al. TSPO imaging using the novel PET ligand [(18)F]GE-180: quantification approaches in patients with multiple sclerosis. EJNMMI Res. 2017;7:89. https:\/\/doi.org\/10.1186\/s13550-017-0340-x.","journal-title":"EJNMMI Res"},{"key":"5887_CR14","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1007\/s00259-017-3799-9","volume":"44","author":"NL Albert","year":"2017","unstructured":"Albert NL, Unterrainer M, Fleischmann DF, Lindner S, Vettermann F, Brunegraf A, et al. TSPO PET for glioma imaging using the novel ligand (18)F-GE-180: first results in patients with glioblastoma. Eur J Nucl Med Mol Imaging. 2017;44:2230\u20138. https:\/\/doi.org\/10.1007\/s00259-017-3799-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5887_CR15","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1038\/s41591-021-01456-w","volume":"27","author":"TA Pascoal","year":"2021","unstructured":"Pascoal TA, Benedet AL, Ashton NJ, Kang MS, Therriault J, Chamoun M, et al. Microglial activation and tau propagate jointly across Braak stages. Nat Med. 2021;27:1592\u20139. https:\/\/doi.org\/10.1038\/s41591-021-01456-w.","journal-title":"Nat Med"},{"key":"5887_CR16","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3389\/fncel.2020.00269","volume":"14","author":"MJ Plastini","year":"2020","unstructured":"Plastini MJ, Desu HL, Brambilla R. Dynamic responses of microglia in animal models of multiple sclerosis. Front Cell Neurosci. 2020;14:269. https:\/\/doi.org\/10.3389\/fncel.2020.00269.","journal-title":"Front Cell Neurosci"},{"key":"5887_CR17","doi-asserted-by":"publisher","first-page":"3318","DOI":"10.1093\/brain\/awaa275","volume":"143","author":"M Sucksdorff","year":"2020","unstructured":"Sucksdorff M, Matilainen M, Tuisku J, Polvinen E, Vuorimaa A, Rokka J, et al. Brain TSPO-PET predicts later disease progression independent of relapses in multiple sclerosis. Brain\u202f: J Neurol. 2020;143:3318\u201330. https:\/\/doi.org\/10.1093\/brain\/awaa275.","journal-title":"Brain : J Neurol"},{"key":"5887_CR18","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1186\/s12974-018-1352-9","volume":"15","author":"MHJ Hagens","year":"2018","unstructured":"Hagens MHJ, Golla SV, Wijburg MT, Yaqub M, Heijtel D, Steenwijk MD, et al. In vivo assessment of neuroinflammation in progressive multiple sclerosis: a proof of concept study with [(18)F]DPA714 PET. J Neuroinflammation. 2018;15:314. https:\/\/doi.org\/10.1186\/s12974-018-1352-9.","journal-title":"J Neuroinflammation"},{"key":"5887_CR19","doi-asserted-by":"crossref","unstructured":"Nutma E, Fancy N, Marzin M, Tsartsalis S, Muirhead RCJ, Falk I, et al. Translocator protein is a marker of activated microglia in rodent 2 models but not human neurodegenerative diseases. 2022. https:\/\/www.researchsquare.com\/article\/rs-1420033\/v1.","DOI":"10.21203\/rs.3.rs-1420033\/v1"},{"key":"5887_CR20","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1186\/s12974-017-1034-z","volume":"14","author":"W Beaino","year":"2017","unstructured":"Beaino W, Janssen B, Kooij G, van der Pol SMA, van Het Hof B, van Horssen J, et al. Purinergic receptors P2Y12R and P2X7R: potential targets for PET imaging of microglia phenotypes in multiple sclerosis. J Neuroinflammation. 2017;14:259. https:\/\/doi.org\/10.1186\/s12974-017-1034-z.","journal-title":"J Neuroinflammation"},{"key":"5887_CR21","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1007\/s00259-019-04369-6","volume":"46","author":"D Van Weehaeghe","year":"2019","unstructured":"Van Weehaeghe D, Koole M, Schmidt ME, Deman S, Jacobs AH, Souche E, et al. [(11)C]JNJ54173717, a novel P2X7 receptor radioligand as marker for neuroinflammation: human biodistribution, dosimetry, brain kinetic modelling and quantification of brain P2X7 receptors in patients with Parkinson\u2019s disease and healthy volunteers. Eur J Nucl Med Mol Imaging. 2019;46:2051\u201364. https:\/\/doi.org\/10.1007\/s00259-019-04369-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5887_CR22","doi-asserted-by":"publisher","first-page":"604","DOI":"10.2967\/jnumed.119.231985","volume":"61","author":"D Van Weehaeghe","year":"2020","unstructured":"Van Weehaeghe D, Van Schoor E, De Vocht J, Koole M, Attili B, Celen S, et al. TSPO versus P2X7 as a target for neuroinflammation: an in vitro and in vivo study. J Nucl Med: Off Publ Soc Nucl Med. 2020;61:604\u20137. https:\/\/doi.org\/10.2967\/jnumed.119.231985.","journal-title":"J Nucl Med: Off Publ Soc Nucl Med"},{"key":"5887_CR23","doi-asserted-by":"publisher","first-page":"4465","DOI":"10.1021\/acschemneuro.1c00641","volume":"12","author":"B van der Wildt","year":"2021","unstructured":"van der Wildt B, Janssen B, Pekosak A, Steen EJL, Schuit RC, Kooijman EJM, et al. Novel thienopyrimidine-based PET tracers for P2Y12 receptor imaging in the brain. ACS Chem Neurosci. 2021;12:4465\u201374. https:\/\/doi.org\/10.1021\/acschemneuro.1c00641.","journal-title":"ACS Chem Neurosci"},{"key":"5887_CR24","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1002\/ana.24754","volume":"80","author":"M Tada","year":"2016","unstructured":"Tada M, Konno T, Tada M, Tezuka T, Miura T, Mezaki N, et al. Characteristic microglial features in patients with hereditary diffuse leukoencephalopathy with spheroids. Ann Neurol. 2016;80:554\u201365. https:\/\/doi.org\/10.1002\/ana.24754.","journal-title":"Ann Neurol"},{"key":"5887_CR25","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/ng.1027","volume":"44","author":"R Rademakers","year":"2011","unstructured":"Rademakers R, Baker M, Nicholson AM, Rutherford NJ, Finch N, Soto-Ortolaza A, et al. Mutations in the colony stimulating factor 1 receptor (CSF1R) gene cause hereditary diffuse leukoencephalopathy with spheroids. Nat Genet. 2011;44:200\u20135. https:\/\/doi.org\/10.1038\/ng.1027.","journal-title":"Nat Genet"},{"key":"5887_CR26","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1177\/0271678X211004146","volume":"41","author":"X Zhou","year":"2021","unstructured":"Zhou X, Ji B, Seki C, Nagai Y, Minamimoto T, Fujinaga M, et al. PET imaging of colony-stimulating factor 1 receptor: a head-to-head comparison of a novel radioligand, (11)C-GW2580, and (11)C-CPPC, in mouse models of acute and chronic neuroinflammation and a rhesus monkey. J Cereb Blood Flow Metab\u202f: Off J Int Soc Cereb Blood Flow Metab. 2021;41:2410\u201322. https:\/\/doi.org\/10.1177\/0271678X211004146.","journal-title":"J Cereb Blood Flow Metab : Off J Int Soc Cereb Blood Flow Metab"},{"key":"5887_CR27","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1073\/pnas.1812155116","volume":"116","author":"AG Horti","year":"2019","unstructured":"Horti AG, Naik R, Foss CA, Minn I, Misheneva V, Du Y, et al. PET imaging of microglia by targeting macrophage colony-stimulating factor 1 receptor (CSF1R). Proc Natl Acad Sci USA. 2019;116:1686\u201391. https:\/\/doi.org\/10.1073\/pnas.1812155116.","journal-title":"Proc Natl Acad Sci USA"},{"key":"5887_CR28","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1007\/s00259-021-05640-5","volume":"49","author":"Y Liu","year":"2022","unstructured":"Liu Y, Jiang H, Qin X, Tian M, Zhang H. PET imaging of reactive astrocytes in neurological disorders. Eur J Nucl Med Mol Imaging. 2022;49:1275\u201387. https:\/\/doi.org\/10.1007\/s00259-021-05640-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5887_CR29","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/s0969-8051(99)00088-8","volume":"27","author":"J Logan","year":"2000","unstructured":"Logan J, Fowler JS, Volkow ND, Wang G-J, MacGregor RR, Shea C. Reproducibility of repeated measures of deuterium substituted [11C]L-deprenyl ([11C]L-deprenyl-D2) binding in the human brain. Nucl Med Biol. 2000;27:43\u20139. https:\/\/doi.org\/10.1016\/s0969-8051(99)00088-8.","journal-title":"Nucl Med Biol"},{"key":"5887_CR30","doi-asserted-by":"publisher","unstructured":"Villemagne VL, Harada R, Dore V, Furumoto S, Mulligan R, Kudo Y, et al. First-in-human evaluation of (18)F-SMBT-1, a novel (18)F-labeled MAO-B PET tracer for imaging reactive astrogliosis. Journal of nuclear medicine: official publication. J Nucl Med. 2022;jnumed.121.263254. https:\/\/doi.org\/10.2967\/jnumed.121.263254","DOI":"10.2967\/jnumed.121.263254"},{"key":"5887_CR31","doi-asserted-by":"publisher","first-page":"253","DOI":"10.2967\/jnumed.120.244400","volume":"62","author":"R Harada","year":"2021","unstructured":"Harada R, Hayakawa Y, Ezura M, Lerdsirisuk P, Du Y, Ishikawa Y, et al. (18)F-SMBT-1: a selective and reversible PET tracer for monoamine oxidase-B imaging. J Nucl Med: Off Publ Soc Nucl Med. 2021;62:253\u20138. https:\/\/doi.org\/10.2967\/jnumed.120.244400.","journal-title":"J Nucl Med: Off Publ Soc Nucl Med"},{"key":"5887_CR32","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.1007\/s00259-020-04855-2","volume":"47","author":"MJ Kim","year":"2020","unstructured":"Kim MJ, Lee JH, Juarez Anaya F, Hong J, Miller W, Telu S, et al. First-in-human evaluation of [(11)C]PS13, a novel PET radioligand, to quantify cyclooxygenase-1 in the brain. Eur J Nucl Med Mol Imaging. 2020;47:3143\u201351. https:\/\/doi.org\/10.1007\/s00259-020-04855-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5887_CR33","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s12974-020-01804-6","volume":"17","author":"S Shrestha","year":"2020","unstructured":"Shrestha S, Kim MJ, Eldridge M, Lehmann ML, Frankland M, Liow JS, et al. PET measurement of cyclooxygenase-2 using a novel radioligand: upregulation in primate neuroinflammation and first-in-human study. J Neuroinflammation. 2020;17:140. https:\/\/doi.org\/10.1186\/s12974-020-01804-6.","journal-title":"J Neuroinflammation"},{"key":"5887_CR34","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1021\/cn500185g","volume":"5","author":"X Zhang","year":"2014","unstructured":"Zhang X, Bian J-S. Hydrogen sulfide: a neuromodulator and neuroprotectant in the central nervous system. ACS Chem Neurosci. 2014;5:876\u201383. https:\/\/doi.org\/10.1021\/cn500185g.","journal-title":"ACS Chem Neurosci"},{"key":"5887_CR35","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.tips.2003.10.007","volume":"24","author":"PK Moore","year":"2003","unstructured":"Moore PK, Bhatia M, Moochhala S. Hydrogen sulfide: from the smell of the past to the mediator of the future? Trends Pharmacol Sci. 2003;24:609\u201311. https:\/\/doi.org\/10.1016\/j.tips.2003.10.007.","journal-title":"Trends Pharmacol Sci"},{"key":"5887_CR36","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.bcp.2017.11.019","volume":"149","author":"BD Paul","year":"2018","unstructured":"Paul BD, Snyder SH. Gasotransmitter hydrogen sulfide signaling in neuronal health and disease. Biochem Pharmacol. 2018;149:101\u20139. https:\/\/doi.org\/10.1016\/j.bcp.2017.11.019.","journal-title":"Biochem Pharmacol"},{"key":"5887_CR37","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1089\/ars.2010.3517","volume":"15","author":"L-F Hu","year":"2010","unstructured":"Hu L-F, Lu M, Hon Wong PT, Bian J-S. Hydrogen sulfide: neurophysiology and neuropathology. Antioxid Redox Signal. 2010;15:405\u201319. https:\/\/doi.org\/10.1089\/ars.2010.3517.","journal-title":"Antioxid Redox Signal"},{"key":"5887_CR38","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1016\/j.tranon.2019.05.017","volume":"12","author":"H Matsumoto","year":"2019","unstructured":"Matsumoto H, Yoshii Y, Baden A, Kaneko E, Hashimoto H, Suzuki H, et al. Preclinical pharmacokinetic and safety studies of copper-diacetyl-bis(N(4)-methylthiosemicarbazone) (Cu-ATSM): translational studies for internal radiotherapy. Transl Oncol. 2019;12:1206\u201312. https:\/\/doi.org\/10.1016\/j.tranon.2019.05.017.","journal-title":"Transl Oncol"},{"key":"5887_CR39","doi-asserted-by":"publisher","unstructured":"Vavere AL, Lewis JS. Cu-ATSM: a radiopharmaceutical for the PET imaging of hypoxia. Dalton Trans. 2007;(43):4893\u2013902. https:\/\/doi.org\/10.1039\/b705989b.","DOI":"10.1039\/b705989b"},{"key":"5887_CR40","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2967\/jnumed.113.132480","volume":"55","author":"JL Dearling","year":"2014","unstructured":"Dearling JL, Packard AB. On the destiny of (copper) species. J Nucl Med. 2014;55:7\u20138. https:\/\/doi.org\/10.2967\/jnumed.113.132480.","journal-title":"J Nucl Med"},{"key":"5887_CR41","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.nucmedbio.2009.11.004","volume":"37","author":"JL Dearling","year":"2010","unstructured":"Dearling JL, Packard AB. Some thoughts on the mechanism of cellular trapping of Cu(II)-ATSM. Nucl Med Biol. 2010;37:237\u201343. https:\/\/doi.org\/10.1016\/j.nucmedbio.2009.11.004.","journal-title":"Nucl Med Biol"},{"key":"5887_CR42","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/BF02988502","volume":"15","author":"A Obata","year":"2001","unstructured":"Obata A, Yoshimi E, Waki A, Lewis JS, Oyama N, Welch MJ, et al. Retention mechanism of hypoxia selective nuclear imaging\/radiotherapeutic agent cu-diacetyl-bis(N4-methylthiosemicarbazone) (Cu-ATSM) in tumor cells. Ann Nucl Med. 2001;15:499\u2013504. https:\/\/doi.org\/10.1007\/BF02988502.","journal-title":"Ann Nucl Med"},{"key":"5887_CR43","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1088\/0031-9155\/54\/7\/017","volume":"54","author":"JP Holland","year":"2009","unstructured":"Holland JP, Giansiracusa JH, Bell SG, Wong LL, Dilworth JR. In vitro kinetic studies on the mechanism of oxygen-dependent cellular uptake of copper radiopharmaceuticals. Phys Med Biol. 2009;54:2103\u201319. https:\/\/doi.org\/10.1088\/0031-9155\/54\/7\/017.","journal-title":"Phys Med Biol"},{"key":"5887_CR44","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.nucmedbio.2011.08.008","volume":"39","author":"Y Yoshii","year":"2012","unstructured":"Yoshii Y, Yoneda M, Ikawa M, Furukawa T, Kiyono Y, Mori T, et al. Radiolabeled Cu-ATSM as a novel indicator of overreduced intracellular state due to mitochondrial dysfunction: studies with mitochondrial DNA-less rho0 cells and cybrids carrying MELAS mitochondrial DNA mutation. Nucl Med Biol. 2012;39:177\u201385. https:\/\/doi.org\/10.1016\/j.nucmedbio.2011.08.008.","journal-title":"Nucl Med Biol"},{"key":"5887_CR45","first-page":"177","volume":"40","author":"JS Lewis","year":"1999","unstructured":"Lewis JS, McCarthy DW, McCarthy TJ, Fujibayashi Y, Welch MJ. Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model. J Nucl Med. 1999;40:177\u201383.","journal-title":"J Nucl Med"},{"key":"5887_CR46","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1021\/jm0104217","volume":"45","author":"RI Maurer","year":"2002","unstructured":"Maurer RI, Blower PJ, Dilworth JR, Reynolds CA, Zheng Y, Mullen GE. Studies on the mechanism of hypoxic selectivity in copper bis(thiosemicarbazone) radiopharmaceuticals. J Med Chem. 2002;45:1420\u201331. https:\/\/doi.org\/10.1021\/jm0104217.","journal-title":"J Med Chem"},{"key":"5887_CR47","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1242\/jcs.043216","volume":"122","author":"C White","year":"2009","unstructured":"White C, Kambe T, Fulcher YG, Sachdev SW, Bush AI, Fritsche K, et al. Copper transport into the secretory pathway is regulated by oxygen in macrophages. J Cell Sci. 2009;122:1315\u201321. https:\/\/doi.org\/10.1242\/jcs.043216.","journal-title":"J Cell Sci"},{"key":"5887_CR48","first-page":"1155","volume":"38","author":"Y Fujibayashi","year":"1997","unstructured":"Fujibayashi Y, Taniuchi H, Yonekura Y, Ohtani H, Konishi J, Yokoyama A. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med. 1997;38:1155\u201360.","journal-title":"J Nucl Med"},{"key":"5887_CR49","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/BF02988690","volume":"14","author":"N Takahashi","year":"2000","unstructured":"Takahashi N, Fujibayashi Y, Yonekura Y, Welch MJ, Waki A, Tsuchida T, et al. Evaluation of 62Cu labeled diacetyl-bis(N4-methylthiosemicarbazone) as a hypoxic tissue tracer in patients with lung cancer. Ann Nucl Med. 2000;14:323\u20138. https:\/\/doi.org\/10.1007\/BF02988690.","journal-title":"Ann Nucl Med"},{"key":"5887_CR50","first-page":"655","volume":"42","author":"JS Lewis","year":"2001","unstructured":"Lewis JS, Sharp TL, Laforest R, Fujibayashi Y, Welch MJ. Tumor uptake of copper-diacetyl-bis(N(4)-methylthiosemicarbazone): effect of changes in tissue oxygenation. J Nucl Med. 2001;42:655\u201361.","journal-title":"J Nucl Med"},{"key":"5887_CR51","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/j.ijrobp.2004.12.057","volume":"61","author":"JA O'Donoghue","year":"2005","unstructured":"O\u2019Donoghue JA, Zanzonico P, Pugachev A, Wen B, Smith-Jones P, Cai S, et al. Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models. Int J Radiat Oncol Biol Phys. 2005;61:1493\u2013502. https:\/\/doi.org\/10.1016\/j.ijrobp.2004.12.057.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5887_CR52","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.2967\/jnumed.109.069021","volume":"50","author":"TG Lohith","year":"2009","unstructured":"Lohith TG, Kudo T, Demura Y, Umeda Y, Kiyono Y, Fujibayashi Y, et al. Pathophysiologic correlation between 62Cu-ATSM and 18F-FDG in lung cancer. J Nucl Med. 2009;50:1948\u201353. https:\/\/doi.org\/10.2967\/jnumed.109.069021.","journal-title":"J Nucl Med"},{"key":"5887_CR53","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1097\/RLU.0b013e31823eaadb","volume":"37","author":"A Kositwattanarerk","year":"2012","unstructured":"Kositwattanarerk A, Oh M, Kudo T, Kiyono Y, Mori T, Kimura Y, et al. Different distribution of (62) Cu ATSM and (18)F-FDG in head and neck cancers. Clin Nucl Med. 2012;37:252\u20137. https:\/\/doi.org\/10.1097\/RLU.0b013e31823eaadb.","journal-title":"Clin Nucl Med"},{"key":"5887_CR54","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.mito.2009.01.011","volume":"9","author":"M Ikawa","year":"2009","unstructured":"Ikawa M, Okazawa H, Arakawa K, Kudo T, Kimura H, Fujibayashi Y, et al. PET imaging of redox and energy states in stroke-like episodes of MELAS. Mitochondrion. 2009;9:144\u20138. https:\/\/doi.org\/10.1016\/j.mito.2009.01.011.","journal-title":"Mitochondrion"},{"key":"5887_CR55","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.nucmedbio.2011.02.016","volume":"38","author":"M Ikawa","year":"2011","unstructured":"Ikawa M, Okazawa H, Kudo T, Kuriyama M, Fujibayashi Y, Yoneda M. Evaluation of striatal oxidative stress in patients with Parkinson\u2019s disease using [62Cu]ATSM PET. Nucl Med Biol. 2011;38:945\u201351. https:\/\/doi.org\/10.1016\/j.nucmedbio.2011.02.016.","journal-title":"Nucl Med Biol"},{"key":"5887_CR56","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1007\/s00259-011-1734-z","volume":"38","author":"M Isozaki","year":"2011","unstructured":"Isozaki M, Kiyono Y, Arai Y, Kudo T, Mori T, Maruyama R, et al. Feasibility of 62Cu-ATSM PET for evaluation of brain ischaemia and misery perfusion in patients with cerebrovascular disease. Eur J Nucl Med Mol Imaging. 2011;38:1075\u201382. https:\/\/doi.org\/10.1007\/s00259-011-1734-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5887_CR57","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3174\/ajnr.A3159","volume":"34","author":"K Tateishi","year":"2013","unstructured":"Tateishi K, Tateishi U, Sato M, Yamanaka S, Kanno H, Murata H, et al. Application of 62Cu-diacetyl-bis (N4-methylthiosemicarbazone) PET imaging to predict highly malignant tumor grades and hypoxia-inducible factor-1alpha expression in patients with glioma. AJNR Am J Neuroradiol. 2013;34:92\u20139. https:\/\/doi.org\/10.3174\/ajnr.A3159.","journal-title":"AJNR Am J Neuroradiol"},{"key":"5887_CR58","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1007\/s00259-003-1130-4","volume":"30","author":"F Dehdashti","year":"2003","unstructured":"Dehdashti F, Mintun MA, Lewis JS, Bradley J, Govindan R, Laforest R, et al. In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM. Eur J Nucl Med Mol Imaging. 2003;30:844\u201350. https:\/\/doi.org\/10.1007\/s00259-003-1130-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5887_CR59","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1016\/s0360-3016(02)04477-2","volume":"55","author":"F Dehdashti","year":"2003","unstructured":"Dehdashti F, Grigsby PW, Mintun MA, Lewis JS, Siegel BA, Welch MJ. Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report. Int J Radiat Oncol Biol Phys. 2003;55:1233\u20138. https:\/\/doi.org\/10.1016\/s0360-3016(02)04477-2.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5887_CR60","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1073\/pnas.98.3.1206","volume":"98","author":"J Lewis","year":"2001","unstructured":"Lewis J, Laforest R, Buettner T, Song S, Fujibayashi Y, Connett J, et al. Copper-64-diacetyl-bis(N4-methylthiosemicarbazone): an agent for radiotherapy. Proc Natl Acad Sci U S A. 2001;98:1206\u201311. https:\/\/doi.org\/10.1073\/pnas.98.3.1206.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5887_CR61","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1093\/jrr\/rrv042","volume":"56","author":"DD McMillan","year":"2015","unstructured":"McMillan DD, Maeda J, Bell JJ, Genet MD, Phoonswadi G, Mann KA, et al. Validation of 64Cu-ATSM damaging DNA via high-LET Auger electron emission. J Radiat Res. 2015;56:784\u201391. https:\/\/doi.org\/10.1093\/jrr\/rrv042.","journal-title":"J Radiat Res"},{"key":"5887_CR62","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/s0969-8051(03)00047-7","volume":"30","author":"A Obata","year":"2003","unstructured":"Obata A, Yoshimoto M, Kasamatsu S, Naiki H, Takamatsu S, Kashikura K, et al. Intra-tumoral distribution of (64)Cu-ATSM: a comparison study with FDG. Nucl Med Biol. 2003;30:529\u201334. https:\/\/doi.org\/10.1016\/s0969-8051(03)00047-7.","journal-title":"Nucl Med Biol"},{"key":"5887_CR63","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.2967\/jnumed.108.051326","volume":"49","author":"JS Lewis","year":"2008","unstructured":"Lewis JS, Laforest R, Dehdashti F, Grigsby PW, Welch MJ, Siegel BA. An imaging comparison of 64Cu-ATSM and 60Cu-ATSM in cancer of the uterine cervix. J Nucl Med. 2008;49:1177\u201382. https:\/\/doi.org\/10.2967\/jnumed.108.051326.","journal-title":"J Nucl Med"},{"key":"5887_CR64","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.2967\/jnumed.113.122671","volume":"58","author":"A Savi","year":"2017","unstructured":"Savi A, Incerti E, Fallanca F, Bettinardi V, Rossetti F, Monterisi C, et al. First evaluation of PET-based human biodistribution and dosimetry of (18)F-FAZA, a tracer for imaging tumor hypoxia. J Nucl Med. 2017;58:1224\u20139. https:\/\/doi.org\/10.2967\/jnumed.113.122671.","journal-title":"J Nucl Med"},{"key":"5887_CR65","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1007\/s11307-020-01516-6","volume":"22","author":"M Nakajo","year":"2020","unstructured":"Nakajo M, Jinguji M, Tani A, Kajiya Y, Nandate T, Kitazano I, et al. [(18)F]-FDG-PET\/CT and [(18)F]-FAZA-PET\/CT hypoxia imaging of metastatic thyroid cancer: association with short-term progression after radioiodine therapy. Mol Imaging Biol. 2020;22:1609\u201320. https:\/\/doi.org\/10.1007\/s11307-020-01516-6.","journal-title":"Mol Imaging Biol"},{"key":"5887_CR66","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1177\/0271678X20923857","volume":"41","author":"PV Little","year":"2021","unstructured":"Little PV, Arnberg F, Jussing E, Lu L, Ingemann Jensen A, Mitsios N, et al. The cellular basis of increased PET hypoxia tracer uptake in focal cerebral ischemia with comparison between [(18)F]FMISO and [(64)Cu]CuATSM. J Cereb Blood Flow Metab. 2021;41:617\u201329. https:\/\/doi.org\/10.1177\/0271678X20923857.","journal-title":"J Cereb Blood Flow Metab"},{"key":"5887_CR67","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.nucmedbio.2012.11.012","volume":"40","author":"DJ Williamson","year":"2013","unstructured":"Williamson DJ, Ejaz S, Sitnikov S, Fryer TD, Sawiak SJ, Burke P, et al. A comparison of four PET tracers for brain hypoxia mapping in a rodent model of stroke. Nucl Med Biol. 2013;40:338\u201344. https:\/\/doi.org\/10.1016\/j.nucmedbio.2012.11.012.","journal-title":"Nucl Med Biol"},{"key":"5887_CR68","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1161\/STROKEAHA.107.485938","volume":"39","author":"M Takasawa","year":"2008","unstructured":"Takasawa M, Moustafa RR, Baron JC. Applications of nitroimidazole in vivo hypoxia imaging in ischemic stroke. Stroke. 2008;39:1629\u201337. https:\/\/doi.org\/10.1161\/STROKEAHA.107.485938.","journal-title":"Stroke"},{"key":"5887_CR69","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1002\/jlcr.3973","volume":"65","author":"T Liu","year":"2022","unstructured":"Liu T, Redalen KR, Karlsen M. Development of an automated production process of [(64) Cu][Cu (ATSM)] for positron emission tomography imaging and theranostic applications. J Labelled Comp Radiopharm. 2022;65:191\u2013202. https:\/\/doi.org\/10.1002\/jlcr.3973.","journal-title":"J Labelled Comp Radiopharm"},{"key":"5887_CR70","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1007\/s00259-004-1756-x","volume":"32","author":"R Laforest","year":"2005","unstructured":"Laforest R, Dehdashti F, Lewis JS, Schwarz SW. Dosimetry of 60\/61\/62\/64Cu-ATSM: a hypoxia imaging agent for PET. Eur J Nucl Med Mol Imaging. 2005;32:764\u201370. https:\/\/doi.org\/10.1007\/s00259-004-1756-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5887_CR71","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.tranon.2017.10.006","volume":"11","author":"Y Yoshii","year":"2018","unstructured":"Yoshii Y, Matsumoto H, Yoshimoto M, Zhang MR, Oe Y, Kurihara H, et al. Multiple administrations of (64)Cu-ATSM as a novel therapeutic option for glioblastoma: a translational study using mice with xenografts. Transl Oncol. 2018;11:24\u201330. https:\/\/doi.org\/10.1016\/j.tranon.2017.10.006.","journal-title":"Transl Oncol"},{"key":"5887_CR72","doi-asserted-by":"publisher","first-page":"e86996","DOI":"10.1371\/journal.pone.0086996","volume":"9","author":"Y Yoshii","year":"2014","unstructured":"Yoshii Y, Matsumoto H, Yoshimoto M, Furukawa T, Morokoshi Y, Sogawa C, et al. Controlled administration of penicillamine reduces radiation exposure in critical organs during 64Cu-ATSM internal radiotherapy: a novel strategy for liver protection. PLoS ONE. 2014;9:e86996. https:\/\/doi.org\/10.1371\/journal.pone.0086996.","journal-title":"PLoS ONE"},{"key":"5887_CR73","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.nucmedbio.2022.02.001","volume":"108\u2013109","author":"C Igarashi","year":"2022","unstructured":"Igarashi C, Matsumoto H, Takahashi M, Hihara F, Tachibana T, Zhang MR, et al. Identification and quantitative structure-activity relationship assessment of trace chemical impurities contained in the therapeutic formulation of [(64)Cu]Cu-ATSM. Nucl Med Biol. 2022;108\u2013109:10\u20135. https:\/\/doi.org\/10.1016\/j.nucmedbio.2022.02.001.","journal-title":"Nucl Med Biol"},{"key":"5887_CR74","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13550-020-00621-5","volume":"10","author":"T Liu","year":"2020","unstructured":"Liu T, Karlsen M, Karlberg AM, Redalen KR. Hypoxia imaging and theranostic potential of [(64)Cu][Cu(ATSM)] and ionic Cu(II) salts: a review of current evidence and discussion of the retention mechanisms. EJNMMI Res. 2020;10:33. https:\/\/doi.org\/10.1186\/s13550-020-00621-5.","journal-title":"EJNMMI Res"},{"key":"5887_CR75","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.nucmedbio.2009.12.011","volume":"37","author":"Y Yoshii","year":"2010","unstructured":"Yoshii Y, Furukawa T, Kiyono Y, Watanabe R, Waki A, Mori T, et al. Copper-64-diacetyl-bis (N4-methylthiosemicarbazone) accumulates in rich regions of CD133+ highly tumorigenic cells in mouse colon carcinoma. Nucl Med Biol. 2010;37:395\u2013404. https:\/\/doi.org\/10.1016\/j.nucmedbio.2009.12.011.","journal-title":"Nucl Med Biol"},{"key":"5887_CR76","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.nucmedbio.2010.08.009","volume":"38","author":"Y Yoshii","year":"2011","unstructured":"Yoshii Y, Furukawa T, Kiyono Y, Watanabe R, Mori T, Yoshii H, et al. Internal radiotherapy with copper-64-diacetyl-bis (N4-methylthiosemicarbazone) reduces CD133+ highly tumorigenic cells and metastatic ability of mouse colon carcinoma. Nucl Med Biol. 2011;38:151\u20137. https:\/\/doi.org\/10.1016\/j.nucmedbio.2010.08.009.","journal-title":"Nucl Med Biol"},{"key":"5887_CR77","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nrd4433","volume":"14","author":"JL Wallace","year":"2015","unstructured":"Wallace JL, Wang R. Hydrogen sulfide-based therapeutics: exploiting a unique but ubiquitous gasotransmitter. Nat Rev Drug Discov. 2015;14:329\u201345. https:\/\/doi.org\/10.1038\/nrd4433.","journal-title":"Nat Rev Drug Discov"},{"key":"5887_CR78","doi-asserted-by":"publisher","unstructured":"Pyun J, McInnes LE, Donnelly PS, Mawal C, Bush AI, Short JL, et al. Copper bis(thiosemicarbazone) complexes modulate P-glycoprotein expression and function in human brain microvascular endothelial cells. J Neurochem. 2022;(3):226-244.\u00a0https:\/\/doi.org\/10.1111\/jnc.15609","DOI":"10.1111\/jnc.15609"},{"key":"5887_CR79","doi-asserted-by":"publisher","first-page":"9365","DOI":"10.1002\/anie.201603813","volume":"55","author":"S Sarkar","year":"2016","unstructured":"Sarkar S, Ha YS, Soni N, An GI, Lee W, Kim MH, et al. Immobilization of the gas signaling molecule H2 S by radioisotopes: detection, quantification, and in vivo imaging. Angew Chem Int Ed Engl. 2016;55:9365\u201370. https:\/\/doi.org\/10.1002\/anie.201603813.","journal-title":"Angew Chem Int Ed Engl"},{"key":"5887_CR80","doi-asserted-by":"crossref","unstructured":"Cheng XT, Huang N, Sheng ZH. Programming axonal mitochondrial maintenance and bioenergetics in neurodegeneration and regeneration. Neuron. 2022;110(12):1899\u20131923.","DOI":"10.1016\/j.neuron.2022.03.015"},{"key":"5887_CR81","doi-asserted-by":"crossref","unstructured":"Eldeeb MA, Thomas RA, Ragheb MA, Fallahi A, Fon EA. Mitochondrial quality control in health and in Parkinson's disease. Physiol Rev. 2022;102(4):1721\u20131755.","DOI":"10.1152\/physrev.00041.2021"},{"key":"5887_CR82","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.tins.2022.01.005","volume":"45","author":"J Cisneros","year":"2022","unstructured":"Cisneros J, Belton TB, Shum GC, Molakal CG, Wong YC. Mitochondria-lysosome contact site dynamics and misregulation in neurodegenerative diseases. Trends Neurosci. 2022;45:312\u201322. https:\/\/doi.org\/10.1016\/j.tins.2022.01.005.","journal-title":"Trends Neurosci"},{"key":"5887_CR83","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/s41574-021-00626-7","volume":"18","author":"JA Amorim","year":"2022","unstructured":"Amorim JA, Coppotelli G, Rolo AP, Palmeira CM, Ross JM, Sinclair DA. Mitochondrial and metabolic dysfunction in ageing and age-related diseases. Nat Rev Endocrinol. 2022;18:243\u201358. https:\/\/doi.org\/10.1038\/s41574-021-00626-7.","journal-title":"Nat Rev Endocrinol"},{"key":"5887_CR84","first-page":"1557","volume":"43","author":"JS Lewis","year":"2002","unstructured":"Lewis JS, Herrero P, Sharp TL, Engelbach JA, Fujibayashi Y, Laforest R, et al. Delineation of hypoxia in canine myocardium using PET and copper(II)-diacetyl-bis(N(4)-methylthiosemicarbazone). J Nucl Med. 2002;43:1557\u201369.","journal-title":"J Nucl Med"},{"key":"5887_CR85","doi-asserted-by":"publisher","first-page":"e009791","DOI":"10.1161\/CIRCIMAGING.119.009791","volume":"13","author":"X Nie","year":"2020","unstructured":"Nie X, Elvington A, Laforest R, Zheng J, Voller TF, Zayed MA, et al. (64)Cu-ATSM positron emission tomography\/magnetic resonance imaging of hypoxia in human atherosclerosis. Circ Cardiovasc Imaging. 2020;13:e009791. https:\/\/doi.org\/10.1161\/CIRCIMAGING.119.009791.","journal-title":"Circ Cardiovasc Imaging"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-022-05887-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-022-05887-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-022-05887-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T17:09:50Z","timestamp":1664557790000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-022-05887-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,3]]},"references-count":85,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["5887"],"URL":"https:\/\/doi.org\/10.1007\/s00259-022-05887-6","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,3]]},"assertion":[{"value":"3 August 2022","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Institutional Review Board approval was not required because the paper is an Editorial.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics\u00a0approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}